arrow
Y

Yoshinobu Saito

Columbia University
H指数:20
被引数:2,129

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years

核苷(酸)类似物治疗>10年的患者中,治疗期间病毒因素影响后续乙型肝炎表面抗原血清清除

2026-04-210
OA
Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis

抗凝治疗反应对肝硬化合并门静脉血栓患者肝脏相关事件的影响

2026-03-010
OAAI
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage

FDA批准药物库筛选鉴定的奥拉瑞芬通过溶酶体损伤抑制HBs抗原分泌

2026-01-160
PRE
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma

NRF2-COX2-PGE2轴驱动免疫冷肿瘤并预测肝细胞癌对联合免疫治疗的耐药性

2026-01-012
PRE
LSECs promote MASH progression via IL-1R1-mediated chemokine production induced by macrophage-derived IL-1β

肝窦内皮细胞(LSECs)通过巨噬细胞来源的IL-1β诱导的IL-1R1介导的趋化因子产生促进MASH进展。

2025-12-020
OAAI
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma

不可切除肝细胞癌中,阿替利珠单抗联合贝伐珠单抗后使用乐伐替尼与乐伐替尼作为一线治疗的比较分析

2025-10-250
PRE
Cohort Profile Update: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study) 2023 update

队列概况更新:东北医疗megabank项目出生队列和三代队列研究(TMM BirThree队列研究)2023年更新

2025-10-010
PRE
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

血清生长分化因子15可作为预测丙型肝炎病毒肝硬化患者病毒清除后预后的新型生物标志物

2025-09-180
OAAI
Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

高血压作为潜在影响不可切除肝细胞癌患者阿替利珠单抗联合贝伐珠单抗治疗疗效的不良事件

2025-09-011
OAAI
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy
2024-10-290
OAAI
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
2024-09-180
OAAI
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis

血清生长分化因子15是一种新型生物标志物,对MASLD患者的肝癌发生具有高预测能力,而与肝纤维化无关

2024-06-032
PRE
The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis

血清tenascin C水平是影响胰腺癌预后的代谢紊乱相关炎症的标志物

2024-05-260
OAAI
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

单细胞分析和宿主遗传学强调先天免疫细胞在新型冠状病毒肺炎严重程度中的作用

2023-04-2418
OAAI
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis

肝星状细胞亚群在肝癌发生中的相反作用

Nature
IF48.5
2022-10-050
PRE